| Not Yet Recruiting | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Rec NCT07355205 | Washington University School of Medicine | Phase 2 |
| Recruiting | Pulmonary Rehabilitation in Advanced Lung Cancer Survivors NCT07104630 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer NCT07250477 | University of California, Davis | Phase 2 |
| Recruiting | [177Lu]Lu-AKIR001 First-in-human Study NCT06639191 | Karolinska University Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non- NCT06848426 | Jiangxi Provincial People's Hopital | N/A |
| Recruiting | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint NCT06463665 | Genelux Corporation | Phase 2 |
| Enrolling By Invitation | Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therap NCT06962449 | Shanghai Chest Hospital | — |
| Not Yet Recruiting | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC NCT06436144 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Active Not Recruiting | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Sub NCT06348199 | Samsung Bioepis Co., Ltd. | Phase 3 |
| Not Yet Recruiting | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC NCT06117644 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Active Not Recruiting | Intrathecal Double Checkpoint Inhibition NCT05598853 | University of Zurich | Phase 1 |
| Active Not Recruiting | Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet) NCT05818449 | University of Cologne | N/A |
| Unknown | Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC NCT05055167 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Terminated | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer NCT04432207 | Imugene Limited | Phase 1 |
| Completed | Immunotherapy in Patient With Poor General Condition NCT04108026 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Completed | Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC NCT04238169 | Xinqiao Hospital of Chongqing | Phase 2 |
| Unknown | Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) NCT03532698 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Terminated | Tumor Mutational Burden in Lung Cancer Patients NCT04289259 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic NCT03526900 | Spanish Lung Cancer Group | Phase 2 |
| Terminated | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With NCT03275597 | University of Wisconsin, Madison | Phase 1 |
| Completed | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC NCT03543683 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Completed | A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer NCT02450539 | Eli Lilly and Company | Phase 2 |
| Completed | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous No NCT01999673 | Peregrine Pharmaceuticals | Phase 3 |
| Completed | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC NCT02047344 | Golden Biotechnology Corporation | Phase 2 |
| Terminated | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced N NCT01798485 | Synta Pharmaceuticals Corp. | Phase 3 |
| Completed | Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial NCT02176369 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Terminated | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer NCT01348126 | Synta Pharmaceuticals Corp. | Phase 2 / Phase 3 |
| Completed | SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer NCT01086254 | Sanofi | Phase 2 |
| Terminated | Phase II Avastin Trial for Stage IIIB/IV NSCLC NCT00766246 | Pharmatech | Phase 2 |